Strategic Partnerships and Collaborations
We have deepened our commercial business pipeline through global in-licensing and strategic partnerships.
These partnerships significantly strengthen our portfolio to bring differentiated science for patients across the world.
Oncology
QiNHAYO™ (Envafolimab)
(SubQ next gen PDL1) /3DM -
India + Emerging Markets
Trastuzumab Rezetecan (SHR-A1811)] -
Emerging Markets
TEVIMBRA® (Tislelizumab) PD1 -
India
Aumolertinib – Emerging Markets
Akynzeo(R) (Netupitant/
Palonosetron) -
India
Brukinsa® (Zanubrutinib) -
India
ISB 2001 (ABBV 2001) – Global
Dermatology
Abrocitinib® - India
Winlevi® Clascoterone - Europe & South Africa
ISB 880 / LAD191 - Global
Telazorlimab (ISB 830) - Global
ISB 830-KB (STAR-0310) - Global
*via Ichnos Glenmark Innovation (IGI), our wholly-owned subsidiary